Introduction
The ability to invade, induce angiogenesis, and avoid immune destruction are important hallmarks of cancer cells (1) . Tumor cells typically invade locally through the extracellular matrix. The cells, which can intravasate into the pre-existing or tumor induced neoangiogenic blood or lymphatic vessels can form metastases in draining lymph nodes and at distant sites. Due to differences in the endothelial and vessel wall structure, lymphatic vessels likely offer pathways of lower resistance for migrating cells, which is associated with the fact that approximately 80% of metastasizing tumors preferentially spread via the lymphatic system (2) .
In addition to the intrinsic properties of tumor cells and the vasculature, the progression of cancer is also dependent on the quality and quantity of anti-tumor immune responses (1) .
Lymphocytes continuously patrol through the blood, lymphoid tissues and lymphatic vasculature during cancer immune surveillance. Pro-inflammatory and cytotoxic immune responses are useful in limiting tumor progression, whereas anti-inflammatory immune cell types often paradoxically promote tumor growth. For instance, regulatory T cells and type 2 macrophages can cause immunosuppression, which is one of the main obstacles in successful cancer treatment (3) (4) (5) . The same cell types also produce multiple pro-angiogenic molecules and thereby contribute to the angiogenic switch in cancer (6) .
Clever-1/Stabilin-1, also known as Feel-1 is a multifunctional molecule conferring scavenging ability on a subset of type 2 macrophages (5, (7) (8) (9) (10) . In these cells it is involved in receptor-mediated endocytosis and recycling, intracellular sorting and transcytosis of altered and normal self-components (11) . While other leukocyte types (monocytes, granulocytes and lymphocytes) are Clever-1 negative, it is also constitutively expressed on afferent and efferent lymphatic endothelial cells, on sinusoidal endothelial cells in the liver and spleen, and on high endothelial venules (8, (12) (13) (14) . Moreover, upon inflammation, it can be induced on blood vessel endothelium, where it mediates the trafficking of lymphocytes, granulocytes and monocytes from the blood into the inflamed tissue (13, (15) (16) (17) .
Clever-1 positive lymphatics and macrophages are found in human cancers and high number of Clever-1 positive macrophages is associated to shorter disease-specific survival in colorectal cancers of advanced stage (15, 18) . This work was designed to elucidate the role of Clever-1 in tumor immunity and in tumor cell trafficking and to test, whether it can be used as a therapeutic target in pre-clinical settings. We generated universal and cell-type selective Clever-1 deficient mice to analyze tumor growth, lymphatic spread and anti-tumor immune responses. We also therapeutically targeted Clever-1 by antibodies during tumor growth in wild-type mice. The results showed that Clever-1 controls tumor progression by mediating leukocyte-subtype selective entrance of tumor-infiltrating leukocytes from the blood into the tumor.
Materials and Methods

Animals
Six to twelve weeks old C57BL/6 WT mice were used in antibody experiments. Clever-1 full knockout (Clever-1 -/-) mice, mice lacking Clever-1 in monocytes/macrophages (Clever- nodes, whereas the footpad ones spread to popliteal lymph nodes. Tumor growth was assessed by luciferase bioluminescence measurements twice a week, using a previously described methodology (23) and also by an electronic caliper (Mitutoyo). The volume of the tumor was calculated according to the formula V = π/6x (shortest diameter) 2 x (longest diameter) as described (24) .
The popliteal lymph node metastases were visually scored at the end of the experiment as follows: 0 -no visible metastasis, 1 -metastases (black spots) encompassing less than half of the LN surface, 2 -metastases covering more than 50% but less than 100% of LN, 3 -whole LN black, but still of normal size, and 4 -enlarged, fully black LN.
The antibody treatments in melanoma-bearing wild-type mice were done with antiClever-1 (25) (originally kind gift of S. Goerdt and then purchased from InVivo Biotech, Hennigsdorf, Germany) or NS-1 control antibody (produced by InVivo Biotech) using prophylactic and therapeutic protocols. In the prophylactic settings, the mice were treated with by subcutaneous injections of the mAbs (50 µg) into the ear 1d before tumor injection followed by intra-peritoneal dosing (100 µg/injection) starting 1d after tumor injection and then repeated every third day. In the therapeutic experiments, no local antibodies were given and the intraperitoneal antibody therapy was first started three days after B16 melanoma cell injections (1 x 10 6 cells in 20 μl).
Research. Ex vivo adhesion assays TIL were isolated from melanomas grown in non-treated wt mice using previously described methodology (26). Briefly, the isolated tumors were minced to small pieces and digested with collagenase D (1 mg/ml, +37°C, 40 min; in the presence of DNase I). The released cells were purified using anti-CD45-PE antibody (BD Pharmingen) and magnetic cell sorting (Mouse PE selection kit, EasySep, Stem Cell Technologies). CD4 positive cells were separated from the blood of wild-type mice using the EasySep mouse CD4+ T cell pre-enrichment kit according to the instructions of the manufacturer. Whole blood after erythrocyte lysis was used as a source of monocytes.
Melanomas were collected from anti-Clever-1 and control antibody-treated mice on day 14, snap frozen and sectioned. The ex vivo adhesion assays were performed as previously described (27). Briefly, isolated TIL and CD4 positive cells from blood were allowed to bind to vessels in the melanoma sections for 30 min at +7 o C under rotatory conditions. In the second set of assays, blood leukocytes from tumor bearing mice were pre-incubated with anti-Clever-1 or control antibody for 30 min and washed twice before application onto the tissue sections. The non-bound cells were then gently decanted off from the sections, and the adherent cells were fixed in 1% glutaraldehyde. The number of leukocytes bound to tumor vessels was counted under dark-field microscopy. These conditions allowed us to discriminate the tumor-infiltrating lymphocytes (small and phase-bright), tumor-infiltrating myeloid cells (mainly macrophages, which are large and have a ruffled appearance) and blood monocytes (large with a ruffled appearance, (28). At least 100 vessels from three independent tumors in both treatment groups were counted and the average number of leukocytes bound per vessel in control treated mice was used to define 100% adherence. skin, metastases and lymph node sections were also stained using biotinylated anti-Clever-1 (1.26) followed by Streptavidin-Alexa Fluor 546. Alternatively, 9-11 (rat anti-human Clever-1, which cross-reacts with the mouse homolog, (30)) or 3-372 (mouse anti-human Clever-1, which cross-reacts with the rabbit homolog) followed by FITC-conjugated anti-rat Ig or mouse Ig was used (13) . For double stainings, anti-LYVE-1 or anti-PV-1 followed by Alexa546-conjugated anti-rabbit IgG (Invitrogen) or Alexa546-conjugated anti-rat IgG (Invitrogen), respectively, was used together with Alexa488-conjugated anti-Clever-1 (9-11). Anti-FoxP3 (a surrogate marker for regulatory T cells from eBioscience) stainings were done from frozen sections fixed with 2% paraformaldehyde, using peroxidase-conjugated rabbit anti-rat Ig (Dako) and 3,3'-diaminobenzidine hydrochloride for visualization. The stainings were analyzed using Olympus BX60 microscope and cell^D version 2.6 software (Soft Imaging Solutions GmbH). Intensity of SPARC staining was analyzed using Image J software.
Co-culture experiments
Blood monocytes and peritoneal macrophages from WT mice were added to the upper compartments of trans-wells (transparent polyester membranes, pore size 0.4 μm, Corning) in medium containing 20 μg/ml anti-Clever-1 (1.26) antibody or negative control antibody, and B16 melanoma (50 000 cells) were simultaneously plated to the lower compartments. After a 3.5 d co-culture, the methanol-fixed membranes with adherent monocytes/macrophages were stained with 5D3 against MR, 9-11 against Clever-1, and negative control antibody followed by FITCanti-rat Ig second stage. Percentages of positive cells were counted under a fluorescence microscope (Olympus BX60). 
Immune array qPCR
Statistical analyses
Two tailed Student's test and Mann-Whitney U-test were used. P values < 0.05 were considered significant.
Results
Induction of Clever-1 in tumor vasculature and macrophages
In normal WT mice Clever-1 is expressed in lymphatics and faintly in high endothelial venules but is practically absent on flat walled vessels and macrophages in lymph nodes ( To study, whether the lack of Clever-1 has an impact on tumor development and metastasis we generated Clever-1 full knockout mice (Clever-1 mice Clever-1 expression in the lymphatics and blood vessels was comparable to tumor-bearing WT mice, whereas almost all Clever-1 positive macrophages had disappeared (Fig. 2C) . Tumors of ENDOclever-1 -/-mice, on the other hand, did not have visible Clever-1 expression on PV-1 positive blood vessels but macrophages and the majority of lymphatic vessels brightly expressed Clever-1 (Fig. 2D ).
Research. 
Retarded tumor growth and metastatic dissemination in absence of Clever-1
The primary B16 tumors remained significantly smaller in Clever-1 -/-mice than in WT mice and the same trend was seen in MACROclever -/-mice when compared to WT mice on day 14, P = 0.057 (Fig. 3A) . However, the sizes between MACROclever -/-tumors were significantly smaller on day 9/10 than the WT tumors, P = 0.009. In the next experiment, primary tumors of also ENDOclever -/-mice tended to remain smaller than those of WT mice ( As the future aim is to test the potential of Clever-1 as a target in human malignancies, we used another cancer model to test, whether anti-Clever-1 mAb interfere with cancer cell migration via the lymphatics. For these experiments, we selected rabbit as a model, as we then could use anti-human Clever-1 mAb 372, which cross-reacts with rabbit Clever-1 ( Supplementary Fig. S3A ), and Clever-1 negative human lymphoma cells (Supplementary Fig.   S3B ). The blockade of lymphatic Clever-1 with this cross-reacting mAb in this model efficiently blocked the trafficking of lymphoma cells from the footpad to the draining popliteal lymph nodes (Fig. 3D) . This supports the notion that lymphatic Clever-1 may promote metastasis formation.
Reduced tumor growth during antibody therapy
To test whether Clever-1 can be used as a therapeutic target in cancer we next used function-blocking antibody against mouse Clever-1. We injected B16 melanoma and EL-4 lymphoma cells, both of which are Clever-1 negative ( Supplementary Figs. S4A and S4B ), subcutaneously into pinna of ears to allow in vivo imaging of metastasis in the neck. In the B16 model, both the primary tumors and the metastases were about 70% smaller in mice treated with anti-Clever-1 antibody in comparison to the control-treated animals, when the treatment was started before the tumor cell injections (Figs. 4A and 4B, Supplementary Fig. S4C ).
In the EL-4 lymphoma model, tumor growth was observed in 9/11 control-treated and 9/10 anti-Clever-1-treated mice. Among the mice with detectable tumor growth, the primary tumors remained significantly smaller in the anti-Clever-1-treated group (Fig. 4C) . The EL-4 metastases in draining lymph nodes were on average 49% smaller on day 11 (p<0.01) and 26% smaller on day 14 in the anti-Clever-1-treated group than in the control antibody-treated group, but this difference did not reach statistical significance (Fig. 4C) .
To evaluate the efficacy of Clever-1 blockade in a clinically relevant therapeutic setting, we then let the B16 tumors grow for three days before starting the antibody therapy. In this model the anti-Clever-1 antibody treatment also led to a statistically significant reduction in primary tumors and metastases on day 20 (Fig. 4D) . Thus, prophylactic and therapeutic neutralization of Clever-1 by mAbs attenuates tumor growth in vivo.
Research. (Fig. 5A) . Number of MRC positive macrophages and FoxP3 positive cells were also reduced both in the primary tumors and metastases of antiClever-1 mAb treated WT mice in comparison to control mAb treated mice (Fig. 5B) . Moreover, by comparing tumors of overlapping sizes in anti-Clever-1 and control treated groups we found that the diminished numbers of intratumoral type 2 macrophages subsequent to the antibody therapy was not dependent on the size of the tumors (Supplementary Fig. S5A ). The reduction of MRC and FoxP3 positive cells was selective since the numbers of intratumoral CD3 and CD8 positive cells were comparable in both treatment groups (Fig. 5B) .
Although Clever-1 has been reported to play a role in angiogenesis in vitro (7) the numbers of intra-tumoral blood vessels (CD31 and PV-1 positive) and lymphatics (CD31 positive and PV-1 negative) were comparable after anti-Clever-1-and control antibodytreatments in wild-type mice (Fig. 5B) . Together these data thus show that the number of regulatory immune cell types is diminished subsequent to targeting Clever-1, but both the blood and lymphatic vasculature remain unchanged (Fig. 5) .
Anti-Clever-1 mAb treatment does not alter scavenging of SPARC or macrophage polarization As Clever-1 on macrophages mediates the uptake of SPARC (9), an extracellular matrix molecule regulating tumor growth, the amount of SPARC could contribute to the reduced tumor growth in anti-Clever-1-treated mice. However, the expression of SPARC was found to be similar in tumors of anti-Clever-1-and control antibody-treated mice (Supplementary Table S1 ). Figs. S5B and S5C) . Notably, presence of saturating anti-Clever-1 mAb concentrations had no effect on this process. Together these data strongly suggest that the antibody treatment does not deplete macrophages and has no direct effect on their M1/M2 polarization. 
Clever-1 mediates binding of TIL to tumor vasculature
Since Clever-1 is involved in the extravasation of leukocytes to lymphoid organs and into sites of inflammation (17) we tested, whether entrance of TIL (or that of their precursors) was inhibited during the antibody therapy. We collected tumors from both anti-Clever-1-and control antibody-treated animals and tested the binding of TIL and peripheral blood CD4 positive T cells isolated from non-treated WT mice to vessels in those tumors ex vivo. Both tumor-infiltrating myeloid cells and lymphocytes bound less efficiently to tumor vessels of anti-Clever-1-treated animals. Also, the adhesion of CD4 positive blood lymphocytes to the tumor vasculature of Clever-1-treated mice was reduced in comparison to those of control antibody-treated mice (Fig.   6A ). Moreover, to test whether monocyte Clever-1 contributes to adherence to the endothelium we treated blood monocytes and lymphocytes (lymphocytes served as controls as they are Clever-1 negative) collected from tumor-bearing mice with anti-Clever-1 mAb in vitro prior to the adhesion assay. Anti-Clever-1 mAb inhibited monocyte binding to tumor vessels by 70%, whereas no inhibition was seen in lymphocyte binding (Fig. 6B) . Thus, anti-Clever-1 therapy may prevent leukocyte entrance into the tumors by targeting Clever-1 both on the vascular endothelium and monocytes and is well in line with the results obtained with MACROclever-/-and ENDOclever-/-mice.
Anti-Clever-1 treatment is responsible for increased immune activation and apoptosis in tumors
To analyze, whether decreased numbers of immunosuppressing leukocyte types in tumors after anti-Clever-1 treatment associates with increased anti-tumor immune response, we performed qPCR immune arrays. Within the TIL (CD45+) population (Fig. 6C) (Fig.   6D ). In the CD45 negative population, the expression of pro-apoptotic Smad7 was increased and the expression of the anti-apoptotic marker Bcl2-like protein 1 (Bcl2l1) was decreased. The enhanced apoptosis of the tumors subsequent to anti-Clever-1 therapy was also confirmed by in situ apoptosis detection. The mean number of apoptotic cells in tumors of anti-Clever-1 antibody-treated mice (n = 4) was 46.4 ± 4.8/high-power field (HPF) and 15.7 ± 5.7/HPF in tumors of control antibody-treated mice (n = 5; P = 0.005).
Anti-Clever-1 therapy does not aggravate autoimmune inflammations
As anti-Clever-1 treatment leads to immune activation in cancer, it might aggravate inflammation in other settings. However, in neutrophil and lymphocyte dominated models of arthritis, induced by anti-collagen II antibodies (CAIA) and collagen (CIA), respectively, the anti-Clever-1 mAb therapy did not modify the disease course (severity or incidence). Similar results were obtained also in arthritis experiments performed with Ncf1 mutated mice, which normally display a severe form of CIA (Supplementary Fig. S6 ). Thus, anti-Clever-1 antibody treatment appears to have different immuno-modulatory effects in inflammation related to cancer and autoimmune diseases. 
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formally verify this hypothesis in vivo, since leukocyte accumulation in the tumor is slow when compared to lymph nodes in an appropriate time window to allow reliable discrimination of homing from local proliferation. Also in humans, Clever-1 is induced both in intratumoral and peritumoral blood vessels and it supports cancer cell binding to tumor vasculature in in vitro assays (15) . The numbers of Tregs and type 2 macrophages, but not other leukocyte subtypes, were reduced in the tumors after Clever-1 mAb treatment. This implies that counter-receptors for Clever-1, which remain to be identified, may be selectively expressed on different leukocyte subtypes.
The results with cell-type specific Clever-1 deficient mice indicate that Clever-1 in tumor endothelium and monocytes/macrophages is decisive in the growth of the primary tumors, 
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